Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis
Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis
复制标题
DOI：
10.1007/s00595-017-1553-3
复制
发表时间：
2018-01-01
期刊：
影响因子：
2.5
通讯作者：
Mori, Masaki
中科院分区：
文献类型：
--
作者：
Wada, Hiroshi;Eguchi, Hidetoshi;Mori, Masaki
同种异体输血对肝细胞癌（HCC）手术后结局的影响仍存在争议。本研究旨在阐明围手术期异体输血对HCC患者肝切除术结果的临床影响，我们分析了5年来在5所大学医院之一接受HCC肝切除术的642例患者的数据。我们采用倾向评分法调查了所有患者和74对配对患者中异体输血对术后结局的影响，在642例患者中，198例（30.8%）接受了围手术期异体输血（AT组），444例（69.2%）未接受异体输血（非AT组）。单因素分析（P < 0.001）和多因素分析（风险比1.521，P = 0.011）显示AT组的总生存率低于非AT组。在使用倾向评分匹配不同的分布后，发现围手术期输血是HCC患者预后不良的因素，在这项多中心研究中，围手术期输血是原发性HCC患者组和倾向评分配对的患者术后预后不良的独立因素。
The influence of allogenic blood transfusion on the postoperative outcomes of hepatocellular carcinoma (HCC) surgery remains controversial. This study aims to clarify the clinical impacts of perioperative allogenic blood transfusion on liver resection outcome in HCC patients.We analyzed data collected over 5 years for 642 patients who underwent hepatectomy for HCC at one of the five university hospitals. We investigated the impact of allogenic blood transfusion on postoperative outcome after surgery in all patients and in 74 matched pairs, using a propensity score.Of the 642 patients, 198 (30.8%) received perioperative allogenic blood transfusion (AT group) and 444 (69.2%) did not (non-AT group). Overall survival was lower in the AT group than in the non-AT group in univariate (P < 0.001) and multivariate analyses (risk ratio 1.521, P = 0.011). After matching the different distributions using propensity scores, perioperative blood transfusion was found to be a poor prognostic factor for HCC patients.In this multi-center study, perioperative blood transfusion was an independent factor for poor prognosis after curative surgery for primary HCC in the patient group and in pairs matched by propensity scores.